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Introduction: Overexpression of MET receptor tyrosine kinase and 
its ligand hepatocyte growth factor (HGF) and MET gene ampli-
fication have been well-documented in non–small-cell lung can-
cer (NSCLC). Activated MET signaling plays an important role 
in human cancer tumorigenesis, metastasis, and drug resistance. 
However, the deregulation of MET/HGF pathway in NSCLC har-
boring ALK gene rearrangement (ALK[+]), which is sensitive to dual 
ALK and MET inhibitor Crizotinib, has not been reported.
Methods: We performed systematic analysis of MET/HGF expres-
sion by immunohistochemistry (IHC) and MET gene amplification 
by dual color, dual hapten bright field in situ hybridization in 19 
ALK(+) and 73 ALK(−) NSCLC tumor tissues from those who had 
clinical ALK rearrangement test done at the Cleveland Clinic from 
August 2010 to January 2013. IHC scoring was interpreted on a stan-
dard four-tier system.
Results: The percentage of MET IHC score 0, 1+, 2+, and 3+ were 
5.5%, 27.8%, 50.0%, and 16.7% in ALK(+) group, compared with 
28.8%, 33.9%, 23.7%, and 13.6% in ALK(−) group, respectively. 
The MET high expression (IHC score 2 or 3) was significantly 
higher in ALK(+) group statistically (66.7% versus 37.3%, p = 0.03). 
 HGF-high expression (IHC score 2 or 3) was 33.3% in ALK(+) and 
15.8% in ALK(−) (p = 0.17). We identified eight cases in ALK(−) and 
one case in ALK(+) tumor who had MET gene amplification (18.4% 
versus 7.1%, p = 0.43) by dual color, dual hapten bright field in 
situ hybridization. No significant correlation between MET protein 
receptor expression and gene amplification was identified.
Conclusions: Our study demonstrated for the first time that 
MET receptor expression, but not MET gene amplification, is 
significantly increased in ALK(+) NSCLC. MET gene amplification 
is a relatively rare event in this unique population compared with 
ALK(−) NSCLC.
Key Words: MET, HGF, ALK Gene rearrangement, Non–small-cell 
lung cancer, Crizotinib.
(J Thorac Oncol. 2014;9: 646–653)
MET is a human tyrosine kinase that functions as the receptor for its natural ligand hepatocyte growth factor 
(HGF), also known as the scatter factor. The deregulation of 
MET/HGF pathway plays an important role in tumorigenesis 
and tumor progression by promoting cell proliferation, survival, 
scattering, motility, and migration, invasion, and metastasis.1 
Studies have shown that MET pathway is activated in many 
solid and hematological malignancies (http://www.vai.org/
met), including lung cancer, and can be altered through ligand 
or receptor overexpression, genomic amplification, MET muta-
tions, and alternative splicing.2,3 MET gene amplification has 
been found as one of the mechanisms of acquired epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors resis-
tance in non–small-cell lung cancer (NSCLC).4–7 MET recep-
tor kinase has been under intensive preclinical investigation for 
over 25 years. MET is now known to be a “druggable” target 
within the human kinome. Early phase clinical investigations 
have shown promising results of MET inhibitors in NSCLC 
and a few of them have been further evaluated in phase 3 lung 
cancer clinical trials recently.1,8 Clinical trial studies now begin 
to shed more insight to suggest the potential predictive utility 
of MET receptor expression level as assayed in IHC as clinical 
biomarker for companion diagnostics development. Moreover, 
there have been case reports documenting tumor response in 
MET amplified NSCLC under treatment by crizotinib.9
Rearrangements of the anaplastic lymphoma kinase (ALK) 
gene was discovered as a driver oncogene in NSCLC in 2007.10 
Although it only represents 5 to 7% NSCLC,10,11 it has made sig-
nificant impact in the treatment of advanced NSCLC as precision 
targeted therapy. ALK rearrangement is found to be primarily 
mutually exclusive with EGFR mutation and KRAS mutation.12,13 
However, the relationship between MET/HGF expression 
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levels and ALK rearrangement in lung cancer is not yet known. 
Crizotinib, an oral ALK inhibitor, has demonstrated dramatic clin-
ical benefit with minimal toxicity in ALK(+) advanced NSCLC.11 
Interestingly, crizotinib was initially developed as a MET inhibi-
tor in preclinical studies and the phase 1 clinical trial.14 The MET/
HGF pathway alterations, such as protein expression and gene 
amplification, have not been reported in NSCLC harboring ALK 
gene rearrangement (ALK[+]). It conceivably may impact the 
efficacy and resistance of crizotinib therapy.
Here, we report the MET and HGF expression by 
immunohistochemistry (IHC) and MET gene amplification 
by dual color, dual hapten bright field in situ hybridization 
(DDISH) in ALK(+) NSCLC compared with ALK(−) con-
trols. Our study demonstrated that MET receptor expression 
but not MET gene amplification is significantly increased in 
ALK(+) NSCLC. We also found that MET gene amplification 
is a relatively rare event in this unique population compared 
with ALK(−) NSCLC.
PATIENTS AND METHODS
Patient Population and Tumor Tissue
This retrospective study was conducted in a cohort of 
92 patients with NSCLC who were seen at the Cleveland 
Clinic (Cleveland, OH) with their tumors clinically tested 
for ALK 2p23 rearrangement by fluorescence in situ hybrid-
ization (FISH; AMV ALK Break Apart FISH Probe Kit, 
Abbott Molecular, Des Plaines, IL) or IHC at the Cleveland 
Clinic Molecular Pathology Laboratory from August 2010 to 
January 2013. All 19 patients whose tumors were found to 
be ALK FISH (+) and had available formalin-fixed paraffin-
embedded (FFPE) tumor tissues were included in this study. 
Forty-seven (47) NSCLC FFPE tumor tissues that had ALK 
rearrangement tested by FISH to be negative during the same 
period were randomly selected and included in the study 
as controls. We also screened 26 tumors of young NSCLC 
patients who were diagnosed at age of 45 years or younger, to 
be included. Our recent published study demonstrated 100% 
sensitivity and specificity of ALK IHC using D5F3 rabbit 
monoclonal antibody (Cell Signaling Technology) linked to 
ultrasensitive bright field detection (OptiView AMP; Ventana 
Medical Systems, Inc., Tucson, AZ) compared with FISH.15 
Hence, the screening of ALK 2p23 translocation in this young 
cohort was conducted using ALK IHC, which was uniformly 
negative. Thus, all of these 21 FFPE samples were included in 
the ALK(−) control group. All FFPE tissue were cut at 5 μm 
and mounted on Superfrost Plus treated slides and the whole 
tissue section on the slide was used for the following stud-
ies. Each case also had one slide stained for hematoxylin and 
eosin to confirm the presence of adequate tumor tissue. The 
clinical data were derived from patients’ electronic medical 
records. Tumor histology was assessed by pathologists (C.F. 
and A.F.) and staging were classified based on American Joint 
Committee on Cancer 7th edition of tumor, node, metasta-
sis staging criteria. None of the patients received any MET 
or HGF inhibitor before the tumor samples were collected. 
This study was conducted in accordance with the Institutional 
Review Board approved study protocol.
Immunohistochemistry
MET IHC 
Staining was performed on a Ventana Benchmark XT 
automated immunostainer (Ventana Medical Systems) using 
a Ventana Optiview DAB IHC Detection Kit with CC1 anti-
gen retrieval. Primary antibody, CONFIRM monoclonal 
rabbit anti-Total c-MET (Ventana Medical Systems, clone 
SP44, catalog 790–4430) was used. Lung cancer cell line 
HCC827 which is known to express MET was used as posi-
tive control. MET IHC scoring was interpreted on a four-tier 
system based on the membranous or cytoplasmic staining 
in greater than 10% tumor cells, which has been previously 
reported in other studies16,17 as follows: none or staining in 
less than 10% tumor cells (0), weak (1+), moderate (2+), and 
strong (3+; Fig. 1). Score 0 and 1+ were considered as low 
MET expression, and score of 2+ and 3+ were considered as 
high MET expression. An additional high MET expression 
criteria of 2+ or 3+ in ≥50% tumor cells, which was used 
in some MET inhibitor clinical trial and study,8,18,19 was also 
evaluated in our study. A H-score that is the sum of each 
intensity multiple its percentage was also calculated for each 
case. Each IHC slide was reviewed and scored independently 
by two pathologists (E.M. and A.L.) who were unaware of 
the clinical details of individual patients. Discordant cases 
were reviewed, discussed and resolved by the two patholo-
gists in a consensus review microscopy session.
HGF IHC
Paraffin slides were dewaxed and rehydrated using 
xylene and gradient alcohols. Antigen retrieval was per-
formed using citrate buffer, pH 6.0. The slides were then 
incubated in 3% hydrogen peroxide for 30 minutes to block 
endogenous peroxidase activity followed by 3% normal rab-
bit serum block (S-5000, Vector Laboratories, Burlingame, 
CA) for another 30 minutes. Endogenous avidin and biotin 
were blocked with Avidin/Biotin Blocking Kit (SP-2001, 
Vector Laboratories) and then samples were incubated with 
primary antibody, goat antihuman HGF (AF-294-NA, R&D 
Systems, Minneapolis, MN) diluted 1:20 in 1.5% normal 
serum, for one hour at room temperature. After washing, 
slides were incubated with rabbit anti-goat biotinylated 
secondary antibody (BA-5000, Vector Laboratories) for 
30 minutes at room temperature followed by Vector Avidin 
Biotin Complex Elite (PK-6100, Vector Laboratories) for 
30 minutes at room temperature. Staining was visualized 
with Vector ImmPACT 3,  3′-diaminobenzidine substrate 
(SK-4105, Vector Laboratories) and slides were counter-
stained with hematoxylin, dehydrated, cleared, and per-
manently mounted. The protocol was optimized to achieve 
best results. We used normal colon tissue and mesotheli-
oma tumor tissue as positive control in the assay. Similar to 
MET IHC, HGF IHC scoring was interpreted on a  four-tier 
system (0, 1+, 2+, 3+; Fig. 2) by the same criteria (both 
membranous and cytoplasmic staining in greater than 10% 
tumor cells, exclude stromal staining) and scoring process 
as described above. Score 0 and 1+ were considered as low 
HGF expression, and score of 2+ and 3+ were considered as 
high HGF expression.
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MET Gene Amplification by DDISH
Fully automated DDISH (Ventana Medical Systems ) 
was performed on a Ventana BenchMark XT (Ventana Medical 
Systems). MET DNA probe and Chromosome 7 reference 
alpha-centromeric probe (CEP7; Ventana Medical Systems) 
were visualized on the same slides, following the manufactur-
er’s protocols (some samples were repeated by modified pro-
tocols). Signals were enumerated in at least 100 tumor nuclei 
per slide, using a light microscope with objectives from ×4 to 
×60. Signal patterns were scored using DDISH criteria devel-
oped for ERBB2 (HER2) DDISH (http://her2dualish.skillport.
com/skillportfe/custom/login/ ventana/login.action;jsessionid
=EAF883D50616EB46CAAA307601F247A1). A small clus-
ter of multiple signals was counted as six signals and a large 
cluster as 12 signals. MET gene amplification was defined as 
the ratio of MET/Chromosome 7 equal or greater than 2.0. The 
data were interpreted by two independent pathologists (E.M. 
and R.T.) and consensus was achieved in all cases.
Statistical Analysis
Continuous variables were compared using nonpara-
metric method Wilson Cox test. χ2 or Fisher’s exact tests were 
used to compare categorical variables. Significance level 
of α ≤ 0.05 was used. All reported p values are two-sided. 
Statistical analyses were performed in JMP.
RESULTS
Patient characteristics are listed in Table 1. With the 
inclusion in the control group of a selective cohort of younger 
patients with diagnosed NSCLC (N = 26), the median age 
of diagnosis of the two study cohorts between ALK(+) and 
ALK(−) patients is well-balanced (51 versus 53 year old, 
p = 0.44). The percent of never-smoker in ALK(+) patients is 
significantly higher than ALK(−) group (52.6% versus 19.2%, 
p = 0.01), which is consistent with literature reports.11,20 
The gender distribution is similar in the two groups. All 
ALK(+) patients had adenocarcinoma except one large cell 
carcinoma (5.3%), whereas 26% of ALK(−) patients had 
 non-adenocarcinoma histology. The percentage of early stage 
(I or II) NSCLC in the control group is only slightly higher 
than the ALK(+) group (24.0% versus 10.6%) because of the 
inclusion of the young cohort patients who underwent surgi-
cal resection with mostly early stage NSCLC. Regardless, the 
differences of the histology and stage distribution between the 
ALK(+) and ALK(−) groups are not statistically significant 
(Table 1) EGFR mutation was detected in three of 50 ALK(−) 
FIGURE 1.  Representative examples of MET immunohistochemical staining with score 0–3 using SP44 monoclonal rabbit 
 anti-Total c-Met (Ventana Medical Systems). The pattern of immunostaining was both cytoplasmic and membranous.
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FIGURE 2.  Distribution of MET IHC signal intensity in ALK(−) 
and ALK(+) NSCLC.
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tumors, but none of the ALK(+), which is consistent with pre-
viously established mutual exclusion of EGFR mutation and 
ALK gene rearrangement.12,13
MET Receptor Protein Expression by IHC
The results of MET IHC were available in 77 patients 
(84%), the missing data are mainly because of lack of tissue. 
The pattern of immunostaining observed was both cytoplas-
mic and membranous. The staining is tumor specific and there 
was no significant background staining of the normal lung tis-
sue. Representative examples of various staining intensities are 
shown in Figure 1. The percentage of MET IHC score 0, 1+, 
2+ and 3+ were 5.5%, 27.8%, 50.0%, and 16.7% in ALK(+) 
group, compared with 28.8%, 33.9%, 23.7%, and 13.6% in 
ALK(−) group, respectively (Fig. 2). The frequency of MET 
high expression (IHC score 2 or 3) was significantly higher in 
ALK(+) group statistically (66.7% versus 37.3%, p = 0.03; 1.8-
fold) than in the ALK(−) group. Using the MET high expression 
definition of 2+ or 3+ in ≥50% cells, the frequency of MET 
high expression remains significantly higher in ALK(+) group 
than ALK(−) controls (58.8% versus 26.7%, p = 0.02; 2.2-fold). 
The median (25th–75th) H-score was also significantly higher 
in ALK(+) group than ALK(−) controls (60 [0–150] versus 152 
[74–211], p = 0.03).
We also observed significantly higher frequency of 
MET receptor high expression in adenocarcinoma than for 
other histology types (52.6% versus 20%, p = 0.02) in our 
study. Finally, we performed subgroup analysis in adenocarci-
noma alone, which demonstrated 70.6% of ALK(+) and 45.0% 
of ALK(−) tumors had MET high expression (p = 0.09). In the 
subgroup of advanced NSCLC (stage 3 or 4, N = 59), MET 
high receptor expression also remained significantly higher 
in ALK(+) tumors compared with the controls (68.8% versus 
37.2%, p = 0.04).
HGF Ligand Expression by IHC
The results of HGF IHC were available in 75 patients 
(82%), the missing data are mainly because of lack of tis-
sue. The pattern of immunostaining observed was mainly 
cytoplasmic. Overall, the IHC staining seems more diffuse 
than MET IHC, with a predominantly intratumoral stain-
ing pattern albeit with some minor stromal positivity also. 
Representative examples of various staining intensities are 
shown in Figure 3. The percentage of HGF IHC score 0, 1+, 
2+, and 3+ were 0%, 66.7%, 27.8%, and 5.5% in ALK(+) 
group, compared with 22.8%, 61.4%, 15.8%, and 0% in 
ALK(−) group, respectively (p = 0.02; Fig. 4). Only 1 case 
with IHC 3+ staining was identified in the entire ALK(+) 
cohort, but none in the ALK(−) cohort. HGF high expression 
(IHC score 2 or 3) was higher in ALK(+) group, although 
the difference was not statistically significant (33.3% versus 
15.8%, p = 0.17). The MET and HGF IHC expression levels 
(score 0–3) were found to be significantly correlated (Pearson 
correlation coefficient = 0.36, p = 0.001).
MET Gene Amplification by DDISH
MET DDISH assay was successfully performed in 63 
cases (68%), including nine repeated cases by using our own 
modified protocol. The lack of valid result in the remain-
ing samples was primary because weak signals for MET 
and or CEP7 and nonspecific pigmentation in background. 
Representative examples of MET gene amplified and non-
amplified cases are illustrated in Figure 5. We identified nine 
cases with MET gene amplification and only one of them was 
ALK(+). However, the percentage difference of MET gene 
amplification between ALK(+) and control group did not reach 
statistical significance (7.1% versus 18.4%, p = 0.43), given 
the limited sample size. The number of cases with MET IHC 
score 0, 1+, 2+, and 3+ here were two (25.0%), zero (0%), two 
(25.0%), and four (50.0%) in nine cases (one case has miss-
ing MET IHC data) with MET gene amplification, and seven 
(17.9%), 18 (46.2%), nine (23.1%), five (12.8%) in 54 cases 
(15 cases have missing MET IHC data) without MET gene 
amplification, respectively. A statistically significant correla-
tion between MET expression by IHC and MET gene ampli-
fication by DDISH also was not identified (coefficient 0.21, 
p = 0.16). We observed that a high proportion of tumor tissues 
had MET aneusomy in both study cohorts (30.8% in ALK(+) 
and 44.4% in ALK(−), p = 0.5), although the clinical impact 
is uncertain.
MET Receptor Expression and Crizotinib 
Response in ALK(+) Patients
Of the 19 ALK(+) patients, 10 were treated with crizo-
tinib, which is a dual ALK/MET inhibitor. Two had docu-
mented complete response and six had partial response. Of 
these 10 patients, eight had MET IHC results available and 
TABLE 1.  Clinical Characteristics of the Study Patients
ALK (−) ALK (+)
pN = 73 N = 19
Age at diagnosis (median, 
25th–75th)
53.0 (43.4–67.5) 51.0 (40.5–63.6) 0.44
Female (%) 38 (52.1%) 8 (42.1%) 0.61
Smoking 0.01
  Never 14 (19.2%) 10 (52.6%)
  Current 27 (37.0) 2 (10.5%)
  Former 32 (43.8%) 7 (36.8%)
Histology 0.36
  Adenocarcinoma 54 (74.0%) 18 (94.7%)
  Squamous 10 (13.7%) 0
  Large cell 4 (5.5%) 1 (5.3%)
  Poorly differentiated 2 (2.7%) 0
  Others 3 (4.1%) 0
Stage
  I 11 (15.5%) 1 (5.3%) 0.69
  II 6 (8.5%) 1 (5.3%)
  III 20 (28.1%) 6 (31.6%)
  IV 34 (47.9%) 11 (57.9%)
EGFR mutation 3 (6.0%) 0 1.0
Death 24 5
Survival month (median, 
25th—75th)
12.6 (4.9–30.0) 32.0 (14.4–83.1) 0.16
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six of them demonstrated high MET expression (2+/3+; two 
complete response and four partial response). Two MET 
 IHC-negative patients had partial response to crizotinib. We 
are not able to draw any statistical conclusion about the asso-
ciation of MET expression and crizotinib response in this 
small sample size cohort. There is one patient in our entire 
cohort whose tumor harbored both ALK rearrangement and 
MET gene amplification, but unfortunately he died before he 
had a chance to receive crizotinib therapy. His tumor exhibited 
moderate MET expression (score 2) and weak HGF expres-
sion (score 1) by IHC.
DISCUSSION
Our study is the first to report that MET expression 
is significantly increased in ALK(+) NSCLC. Tsuta et al21 
studied MET pathway alteration in 906 surgically resected 
NSCLC cases, which were further divided by EGFR gene 
mutation or ALK gene rearrangement. They found the 
FIGURE 3.  Representative examples of HGF IHC staining with score 0 to 3 using a human HGF affinity purified goat polyclonal 
antibody (R&D). The pattern of immunostaining was mainly cytoplasmic.
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FIGURE 4.  Distribution of HGF IHC signal inten-
sity in ALK(−) and ALK(+) NSCLC.
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c-MET, p-MET expression, and MET gene copy number 
were similar in 17 ALK(+) NSCLC compared with the rest 
of the cohort. A few methodology differences are notice-
able between ours and the study by Tsuta et al21. MET IHC 
staining intensity variation among different tumors and 
intratumoral heterogeneity are rather often seen. A four-tier 
(0–3) intensity scoring system is often used in most stud-
ies but a universally accepted level of cutoff for MET high 
expression has not been established yet. In the study Tsuta 
et al21, c-MET IHC positivity was defined as “those exhib-
iting staining in ≥10% of cells” and the staining intensity 
was not part of the definition. This may account for sub-
stantial variability in data interpretation. Regardless, they 
reported c-MET-positive in 26.4% ALK wild type, which is 
comparable with our result in ALK(−) group (37.3% using 
MET 2+ or 3+ in ≥10% cells, 26.7% using MET 2+ or 3+ in 
≥50% cells), the study by Dziadziuszko et al19 (25% using 
MET 2+ or 3+ in ≥50% cells) and our previous study.22 
More importantly, the study by Tsuta et al21 was conducted 
in surgically resected samples, whereas our cases are most 
metastatic NSCLC. It is possible that MET expression lev-
els have significant difference between resectable and meta-
static ALK(+) NSCLC. So the different conclusion is likely 
related to sample selection and possible different definition 
of MET high expression.
The clinical and therapeutic implications of higher MET 
receptor expression in ALK(+) NSCLC patients are currently 
unknown. Crizotinib was demonstrated as a bona fide MET 
inhibitor in a previous case report, a NSCLC patient with de 
novo MET amplification but no ALK rearrangement achieved 
a rapid and durable respond to crizotinib.9 Because of crizo-
tinib is a dual inhibitor of MET and ALK, one may postulate 
that the status of MET expression may impact the efficacy 
of crizotinib in ALK(+) NSCLC under therapy. Nonetheless, 
our study consists of only a small cohort of ALK(+) patients 
who were treated with crizotinib and we are not able to 
test the hypothesis if MET high expression is associated 
with tumor response and clinical outcomes from crizotinib 
therapy. Overall, our results here represent an interesting 
 hypothesis-generating observation that warrants further 
studies in larger cohorts. The oncogenic role and molecu-
lar mechanism of high MET expression in ALK(+) NSCLC 
is particularly worthy of further investigation. Our results 
raise a question whether there might be cross-talk signaling 
between the oncogenic rearranged-ALK and MET activation 
through deregulated expression of the receptor, although the 
observed high MET expression could alternatively represent 
only a bystander effect in this unique molecular subgroup of 
ALK(+) NSCLC. The underlying mechanism for high MET 
expression in ALK(+) NSCLC could be MET gene amplifi-
cation (unlikely in our cohort), transcriptional upregulation, 
alternative splicing or mutation. Unfortunately, there was not 
sufficient sample and tissue materials to further characterize 
the MET gene expression level, alterations, and mutations 
in the MET high expression tumors, especially in ALK(+) 
NSCLC. Regardless, the potential combined therapeutic 
effect of MET inhibitor plus ALK inhibitor (especially the 
second-generation ones such as LDK-378, which does not 
possess MET inhibitory activity) would be of great interest 
to further explore.
High MET expression has recently been identified as 
potential biomarker for patient selection for MET inhibitory 
agents, which has been shown in the phase 2 trial of MET 
inhibitor tivantinib (ARQ197) in advanced HCC,18 the phase 
3 tivantinib in combination with erlotinib in advanced NSCLC 
(MARQUEE) trial8 and the phase 2 trial of onartuzumab 
(MetMAb) combined with erlotinib in advanced NSCLC.18 
The inclusion criterion of high MET expression in patient 
selection in some ongoing phase 3 trials reflects our current 
emerging understanding of MET expression level in relation 
to therapeutic outcomes and their prediction.
MET gene amplification has previously been evalu-
ated in preclinical and clinical studies. Multiple studies have 
reported primary MET gene amplification to be in the wide 
range of 2 to 21% in NSCLC,2,19,23,24 although its impact on 
clinical outcomes such as survival is still controversial.25,26 
Correlation between MET expression and MET gene ampli-
fication has been reported in some previous studies,16,19,21 
although some controversies remain.27,28 We found that the 
correlation between MET receptor expression and gene 
amplification was quite poor in our study. The variation of 
tumor sample characteristics, testing methods, and the defi-
nition of MET gene amplification, may explain some of the 
outcome differences among reported studies. In our study, we 
found that MET gene amplification is uncommon (one of 19 
patients) in ALK(+) NSCLC, but more frequent in ALK(−) 
FIGURE 5.  Representative examples of MET gene amplification by dual probe (black MET probe and red Chromosome 
7 probe), dual hapten bright field in situ hybridization (DDISH). MET gene amplification is defined as the ratio of MET/
Chromosome 7 ≥ 2.0.
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NSCLC. Our results indicate MET gene amplification may 
not be the predominant underlying genomic mechanism that 
activates MET signaling pathway in ALK(+) NSCLC. Instead, 
other alternative mechanisms such as MET gene upregula-
tion, alternative splicing or mutation would be worth further 
exploration, especially in ALK(+) NSCLC. Unfortunately, we 
do not have sufficent sample and tissue available to test these 
hypotheses.
MET gene amplification was tested traditionally 
by quantitative real-time polymerase chain reaction or 
FISH.2,23,24 The DDISH was initially developed for HER2 
gene amplification in breast cancer and study showed near-
perfect agreement between the PathVysion and the DDISH 
assays.29 Dziadziuszko et al19 also accessed MET gene copy 
number by silver in situ hybridization (same as DDISH) in 
surgically resected NSCLC. The success rate of DDISH in 
the 189 samples was 74%. We are currently evaluating the 
concordance of MET DDISH and FISH in solid tumors. 
DDISH has been recently used in MET gene amplification in 
NSCLC and other malignancies.16,17,19 Compared with tradi-
tional FISH, DDISH has several potential advantages. First, 
assessment can be made using conventional light micros-
copy with preserved cell morphology based on an automated 
platform. Additionally, the DDISH slides are more stable 
and can be preserved for review for several years. Compared 
with quantitative real-time polymerase chain reaction, which 
was often used in detecting MET gene amplification, DDISH 
is a fully automated process, may be more easily applied in 
routine clinical practice and preserves morphologic context 
while assessing genotype.
Our study has certain limitations. We included some 
young patients with surgical resected NSCLC in the ALK(−) 
control group which introduced some imbalance between the 
two groups, including age, histology, and stage distribution. 
However, these differences were not statistically significant 
between the two groups. Dziadziuszko et al19 studied MET 
protein expression by IHC in surgically resected NSCLC and 
found no difference among different histology or pathological 
stages. Our study has a relative small sample size and confir-
mation in a larger study is warranted.
In summary, our study evaluated the MET signal-
ing pathway, using assays to investigate MET and HGF 
expression levels and MET gene amplification in a unique 
population of ALK(+) NSCLC that is known to be sensi-
tive to dual ALK and MET inhibitor crizotinib. Compared 
with ALK(−) NSCLC, we found that MET receptor expres-
sion is significantly higher in the ALK(+) group. MET 
gene amplification is a rare event in this particular patient 
population, suggesting that it is unlikely the predominant 
mechanism of inducing high MET expression and pathway 
activation in ALK(+) NSCLC. Validation of our findings in 
an independent study with larger sample size is of interest 
and warranted.
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